To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Scientific result | Metabolomics | Cancer | Biomarkers
The TIRO laboratory of the SHFJ (Nice), in collaboration with the "Centre de lutte contre le cancer Antoine Lacassagne", identifies for the first time discriminating biomarkers of high-grade invasive breast tumors, using a non-targeted metabolomics approach performed on surgical specimens and cytoponctions from patients at different stages of malignancy. A step towards better patient stratification and, consequently, better care.
Breast cancer is a heterogeneous disease with multiple biological, molecular and histological subtypes. In such a context, metabolomics is a promising approach, since it is as close as possible to the patient's phenotype, paving the way towards the identification of signature biomarkers and consequently towards better patient stratification. Studying metabolites in breast cancer could help to understand how a defective metabolism can trigger cancerous processes, and alterations in the metabolome may also be used as potential indicators of cancer aggressiveness. According to the authors of the present study, there is no published work that specifically distinguishes high-grade breast tumors by metabolomics. In this study, researchers performed an untargeted metabolomic analysis of breast tumors in 51 patients treated at the Nice Anti-Cancer Center between 2013 and 2016 (stage I to IIIB cancers) and 49 patients treated at another institution (Dijon Anti-Cancer Center) between 2007 and 2012 (stage IIA to IV cancers). The first series of patients was used to create a "training" database, to provide a discriminating model, and the second series provided "validation" data. The authors identified a metabolomic signature for high-grade invasive tumors with AUCs of 0.88, representing a nearly 90% probability of ability to discriminate high-grade versus lower-grade tumors. They identified several biomarkers of tumor aggressiveness, such as N1,N12-diacetylspermine and catabolites of tryptophan metabolism, both of which are involved in the inhibition of the immune response. This work provides new information on the biological mechanisms underlying the aggressiveness of breast tumors. The biomarkers identified should make it possible to develop new strategies for better stratification of patients in the various immunotherapy clinical trials, and ultimately to obtain personalized medical care. Contacts : Thierry Pourcher (firstname.lastname@example.org ou email@example.com) or Caroline Bailleux (firstname.lastname@example.org)
Caroline Bailleux, David Chardin, Jocelyn Gal, Jean-Marie Guigonis, Sabine Lindenthal, Fanny Graslin, Laurent Arnould, Alexandre Cagnard, Jean-Marc Ferrero, Olivier Humbert, Thierry Pourcher Metabolomic Signatures of Scarff-Bloom-Richardson (SBR) Grade in Non-Metastatic Breast Cancer. Cancers (Basel), 2023 ; 15(7 ):1941 https://dx.doi.org/10.3390/cancers15071941
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.